Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease

Trial Profile

A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Cushing syndrome
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2018 Planned End Date changed from 24 Jun 2021 to 7 Jan 2022.
    • 13 Dec 2018 Planned initiation date changed from 5 Dec 2018 to 31 Jan 2019.
    • 25 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top